Journal: Scientific Reports
Article Title: DPP an extracellular matrix molecule induces Wnt5a mediated signaling to promote the differentiation of adult stem cells into odontogenic lineage
doi: 10.1038/s41598-024-76069-7
Figure Lengend Snippet: DPP stimulation of DPSCs activate Wnt5a signaling. A . DPSCs were treated with DPP (500ng/ml) in the presence and absence of the NF-κB inhibitor TPCA-1. Stimulation was done at varying time points. Total levels of Wnt5a were examined by Western blotting. The densitometric ratios of Wnt5a normalized to actin are shown. B . DPSCs were treated with or without TPCA-1 for 1 h, followed by addition of DPP. The condition media was harvested at the times indicated. WNT5A concentration measured by direct ELISA, and mean and SD ( n = 8) were plotted, *: p < 0.05; ** p < 0.01. C . DPSCs were treated with DMSO (no inhibitor), TPCA-1 and JSH-23. Cells were stimulated with DPP at 500ng/ml for the indicated time points. Expression of Wnt5a gene expression levels were determined by RT-PCR. Fold change was obtained relative to 0 h. D . DPSCs were co-transfected with Wnt5a promoter luciferase plasmids or NF-κB RE luciferase plasmids and treated with DMSO (no inhibitor) and TPCA-1 followed by stimulation with DPP at 0, 250, 500ng/ml. Luciferase activities were measured after 48 h. Mean values with standard deviation for Wnt5a and NF-κB RE promoter activities were normalized to pCMV Renilla and transfection controls to Firefly/Renilla and plotted. Activity was abrogated when cells were treated with TPCA-1. E . ChIP assay was conducted with DPSCs treated with DPP for 0, 1 and 2 h as described in “Materials and Methods” using an anti-NF-κB antibody and the immunoprecipitated DNA was analyzed by qPCR using primers for the NF-κB binding site on the Wnt5a promoter. Mean values with standard deviation for fold enrichments of target DNA fragments, normalized to IgG antibody were plotted. *< 0.05; **<0.01.
Article Snippet: In addition, Wnt5a recombinant protein (500ng/ml, R & D Systems or PF-L6 (1nM, a kind gift from AntlerA Therapeutics were used as positive controls to treat DPSCs to monitor nuclear accumulation of β-Catenin.
Techniques: Western Blot, Concentration Assay, Direct ELISA, Expressing, Reverse Transcription Polymerase Chain Reaction, Transfection, Luciferase, Standard Deviation, Activity Assay, Immunoprecipitation, Binding Assay